Brief: Annovis Bio Announces Full Enrollment Of Its Phase II/III Alzheimer’S Disease Trial
27/11/2023 14:00
Nov 27 (Reuters) - Annovis Bio Inc ANVS.N :
* ANNOVIS BIO ANNOUNCES FULL ENROLLMENT OF ITS PHASE II/III
ALZHEIMER’S DISEASE TRIAL, EXCEEDING ORIGINAL PROJECTIONS
* ANNOVIS BIO INC - EFFICACY AND SAFETY ANALYSIS REVIEWED BY
DSMB
RECOMMENDED THAT ANNOVIS CONTINUE TRIAL AS ORIGINALLY DESIGNED
* ANNOVIS BIO INC - EXPECT DATA FROM STUDY TO READ OUT BY
END OF
MARCH 2024
Source text for Eikon: ID:nGNX3vfCNT
Further company coverage: ANVS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman